glp 1 disorders Patients with eating are seeking — and getting — GLP-1s An analysis on the role

[DOI] [PubMed] [Google Scholar] 31.Wilding J.P.H., Batterham R.L., Calanna S., Davies M., Van Gaal L.F., Lingvay I., et al

The likelihood of nerve damage increases with age, due to the higher prevalence of chronic disease in seniors

The key is proactive treatment, not reactive

Pharmacol Res 2020;152:104615.ArticlePubMed 18

In clinical studies, GLP-1 receptor agonists have been associated with modest reductions in LDL cholesterol and total cholesterol, with more variable effects on triglycerides depending on the specific agent and study population

Early preclinical studies in experimental diabetes demonstrated toxicities such as anemia, thrombocytopenia, splenomegaly, lymphadenopathy, lung histiocytosis, mortality with multiple organ pathology, gastrointestinal, and central nervous system toxicity